Events & Workshops
Self Explorers ~ Empowering Community ~ Float Integrations
ONE LOVE FLOAT IS TURNING 4!
JUNE 28TH 7-9pm
Join us for an old school house party!
Summer Solstice | Full moon | our Being Born day - so many rad things to celebrate in one floaty mash-up!
Click here to join the facebook event
- DJR3 in the hooouse throwing down some sweet beats
- Open Jam ~ bring your instruments
- Kava elixirs and Cacoa
- Fire Ceremony
FLOAT FOR MAPS - PTSD RESEARCH
We are excited to announce that for the entire month of July, we are launching a float campaign to raise funds for groundbreaking post-traumatic stress disorder (PTSD) research being conducted by Multidisciplinary Association for Psychedelic Studies (MAPS) with 15% of every standard float session purchased.
Why We’re Excited To Support MAPS
MAPS’ biggest project to date is MDMA assisted psychotherapy to treat PTSD, which demonstrated groundbreaking results with Phase 2 trials. All participants had chronic, treatment-resistant PTSD, and had suffered from PTSD for an average of 17.8 years. 68% of the 107 participants no longer showed symptoms after just 3 sessions of MDMA-assisted psychotherapy. Additional follow up studies showed that these benefits were sustained an average 45 months later, , something that is nearly unheard of in traditional treatments for PTSD. Similar success in Phase 3 will lead to an FDA approved treatment option for veterans or anyone with trauma.
MAPS has taken huge steps to implement a viable, rigorously tested scientific system of trial MDMA therapy. MAPS needs $500,000 to complete the final trial. With our help, this treatment can be made available to the 25,000,000 people who suffer from serious trauma across the globe.
What is MAPS?
Founded in 1986 by Rick Doblin, Ph.D., MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS’ most recent study is using MDMA-assisted psychotherapy for the treatment of severe PTSD. To learn more, visit the MAPS website: maps.org
MAPS Success Treating PTSD
MAPS’ Phase 2 trials of MDMA-assisted psychotherapy for PTSD had 107 participants, all of which had chronic, treatment-resistant PTSD. Patients in this trial had experienced, on average, 17 years of debilitating PTSD, limiting their quality of life, relationships, successes, and so much more. Upon completion of the trial, receiving only two to three sessions of MDMA assisted psychotherapy, 56% no longer qualified for PTSD at their 2-month follow-up. At the 12-month follow-up, 68% no longer had PTSD.
MAPS had breakthrough results on their Phase 2 trials of MDMA-assisted psychotherapy for PTSD, and are now conducting Phase 3 trials, the final stage of research before the U.S. Food and Drug Administration (FDA) can approve a new prescription treatment. MAPS currently aims to submit its New Drug Application to the FDA in 2021 for approval. Drug development is expensive, but with our help, MAPS will be able to make this PTSD treatment widely available to the 25 million people in the world who are suffering from serious trauma.
If you've floated before, you understand the powerful potential of spending time with your consciousness, devoid of stimuli, totally present to what and who you are. We believe floating to be the most powerful integration tool available to assist in the process of continued self-acceptance. One of the most compelling effects of MDMA-assisted psychotherapy is the treatment’s ability to break down mental blocks in the psyche, facilitating breakthroughs of radical self-acceptance in patients previously crippled by PTSD. We, as a float center, are wholly committed to facilitating mental, physical, and spiritual well-being--we believe in the power of honestly connecting to oneself and we see psychedelic therapy as an undeniably effective tool for doing so. Please join us in supporting this incredible research!